Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

J&J ordered to pay $572m to Oklahoma over opioid crisis

0
SHARES

The pharmaceutical company is planning to appeal the decision to pay the state for damages relating to the US opioid crisis.

Johnson & Johnson (J&J) have been ordered by an Oklahoma judge to pay $572 million in damages for the role it played in developing the US opioid addiction crisis. The case is the first of its kind to go to trial.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Judge Thad Balkman said that Janssen, a division of J&J, deceptively promoted highly addictive prescription painkillers. J&J promoted its drugs by telling doctors and patients that “there was a low risk of abuse and a low danger,” in the drugs, according to Balkman.

“The defendants Janssen and J&J’s misleading marketing and promotion of opioids created a nuisance,” Balkman said.

The ruling states that J&J will fund an abatement plan for care of addicts, families and communities affected.

“Janssen did not cause the opioid crisis in Oklahoma and neither the facts nor the law support this outcome,” said J&J executive vice president Michael Ullmann. The company have stated that they will appeal the decision.

Purdue Pharma and Teva Pharmaceuticals, both accused in the same suit, settled with Oklahoma before the case went to trial. Purdue agreed to pay $270 million and Teva negotiated an $85 million settlement.

More than 40 states are planning to pursue similar claims against the pharmaceutical industry.

Share via
Share via